CTRI/2015/08/006087进行中（未招募）3 期
A Phase III, Open Label, Randomized, Multicenter, Parallel Group Trial to Assess the Efficacy and Safety of the Fixed Dose Combination of Arterolane Maleate 37.5 mg and Piperaquine Phosphate (PQP) 187.5 mg Dispersible Tablets in Comparison with Chloroquine Phosphate in Pediatric Patients with Acute Uncomplicated Plasmodium Vivax Malaria.
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients must fulfil the following inclusion criteria to be eligible for enrolment into the study:
- •1.Children of either sex (male or female) aged between 6 months to 12 years (both inclusive).
- •2.Parent/Guardian/LAR willing to undergo audio visual recording of the consent process and provide a written informed consent by parent/guardian/LAR. If parent/guardian/LAR is unable to provide informed consent in writing, a thumbprint on informed consent document to indicate consent in the presence of at least one witness is acceptable.
- •3.Minimum body weight of 5 kg.
- •4.Presence of acute symptomatic uncomplicated malaria with a diagnosis confirmed by a positive blood smear with asexual forms of P. vivax parasites >=250/ µL of blood.
- •5.Absence of acute severe malnutrition (defined as weight-for-height below -3 standard deviation of WHO normalized reference values and mid-upper arm circumference <115 mm)
- •6.Able to take drugs under study by the oral route
- •7.Minimum Haemoglobin (Hb) level of >8 gm/dL.
- •8.Presence of fever (axillary temperature >=37.5 °C or oral >=38 °C) or a history of fever in the past 24 hours.
- •9.Willingness and ability to comply with the study protocol for the duration of the study.
排除标准
- •If any of the following conditions apply, the patient should not be enrolled in the study.
- •1.Known allergy to arterolane maleate, artesunate, artemisinin derived products, piperaquine, chloroquine, primaquine, excipients of these drugs or any other related drugs.
- •2.Patients with severe malaria as per WHO criteria.
- •3.Presence of general danger signs of severe malaria among children 5 years old (as per WHO)
- •4.Mixed infection with another Plasmodium species at the time of presentation (including P. falciparum, P. ovale and P. malariae).
- •5.Infants with a history of hyperbilirubinemia during the neonatal period.
- •6.Patients with history of hemolytic anaemia or methemoglobinemia.
- •7.Use of concomitant medications that may induce haemolysis or haemolytic anaemia or depressants of myeloid element of the bone marrow.
- •8.Any antimalarial treatment during 1 month prior to screening, as assessed by medical history.
- •9.Gastrointestinal dysfunction that could alter absorption or motility (e.g., diarrhea defined as 3 episodes of watery stools in the previous 24 hours or patients who have had 3 episodes of vomiting within 24 hours prior to screening).
- •10.Ongoing prophylaxis with drugs having antimalarial activity such as cotrimoxazole, doxycycline & malarone.
- •11.Patients with significant disease(s), disorder(s) other than malaria that in the opinion of the Investigator may (i) put the patient at risk because of participation in the study or (ii) interfere with the study evaluations or (iii) cause concern regarding patientsâ?? ability to participate in the study.
- •12.Electrocardiogram (ECG) abnormalities with clinical significance or relevance that require urgent management, including QTc interval 450 msec at screening and cardiac conduction disorders, with the exception of right bundle branch block.
- •13.Patients with known significant renal or hepatic impairment or electrolyte imbalance indicated by any of the following laboratory evaluations at screening:
- •Serum creatinine 1.5 Ã? upper limit of normal (ULN)
- •Aspartate transaminase 2.5 Ã? ULN
- •Alanine transaminase 2.5 Ã? ULN
- •Serum bilirubin 3 mg/dL
- •Serum potassium Lower limit of Normal (LLN)
- •Serum Sodium LLN
- •14.Patients who have had a splenectomy as confirmed by history or clinical examination.
- •15.Patients who are G6PD deficient indicated by laboratory investigation at screening.
- •16.Patients with history of any retinal/ visual field defects or auditory defects of any etiology assessed on the basis of history.
- •17.Patients with psoriasis and porphyria assessed on the basis of history.
- •18.Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6 (flecainide, metoprolol, imipramine, amitriptyline, clomipramine, etc)
- •19.Participation in any investigational drug study at least 3 months prior to screening.
研究者
相似试验
已完成
3 期
A clinical trial to evaluate the efficacy and safety of alpha,beta-arteether in patient of P. falciparum malaria.CTRI/2010/091/000169incoln Pharmaceuticals Ltd
已完成
3 期
A Phase III, Multicenter, Randomized, Open Label, Active Controlled, Parallel Group Study To Compare The Safety And Efficacy Of Acyclovir 1200 mg -Sustained Release With Acyclovir 800 mg- Immediate Release In Immunocompetent Patients With Uncomplicated Herpes Zoster.CTRI/2009/091/000044FDC Limited,142-148, S.V.Road, Jogeshwari (W), Mumbai - 400102, Maharashtra, India
已完成
3 期
A Clinical study To evaluate Efficacy and Safety of FDC of Meropenem 1 gm Plus Tazobactam 125mg/250mg injection For the Treatment of Patients with Gram Negative Infection Including Pseudomonas aeruginosaCTRI/2013/02/003401Aqua Vitoe Laboratories
尚未招募
3 期
A Study To Evaluate The Efficacy And Safety of Aceclofenac Topical Ointment with Voveran Emulgel® (Diclofenac Sodium) For The Treatment of Acute Musculoskeletal ConditionsCTRI/2020/10/028642Panacea Biotec Pharma Ltd
尚未招募
3 期
A Study To Evaluate Efficacy And Safety of Aceclofenac Combination Topical Ointment in Comparison to Reference Product HIFENAC GEL® in Management of Acute Pain in Musculoskeletal Conditions.CTRI/2022/03/041507Panacea Biotec Pharma Ltd